Suchergebnisse - "Pestano, Linda A"

PubPharm (20)

1

Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi-ascending dose study with a bioequivalence arm in healthy volunteers

enthalten in: Clinical and translational science | 2024

von Kirkpatrick, D. | Evans, C. | Pestano, L. | +4

2

Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers

enthalten in: Clinical and Translational Science | 2024

von Kirkpatrick, D. | Evans, C. | Pestano, L. | +4

3

A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin

enthalten in: The Journal of investigative dermatology | 2019

von Gallant-Behm, C. | Piper, J. | Lynch, J. | +9

4

Treatment of B-Cell Cancers With Anti-CD70 Antibody-Drug Conjugates

enthalten in: Europäisches Patentamt | 2018

von LAW CHE-LEUNG | WAHL ALAN F | SCHOLLER NATHALIE | +1

5

Anti-CD70 Antibody-Drug Conjugates and Their Use for the Treatment of Cancer and Immune Disorders

enthalten in: Europäisches Patentamt | 2018

von LAW CHE-LEUNG | WAHL ALAN F | SCHOLLER NATHALIE | +1

6

A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds

enthalten in: Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society | 2018

von Gallant-Behm, C. | Piper, J. | Dickinson, B. | +3

7

A synthetic microRNA‐92a inhibitor (MRG‐110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds

enthalten in: Wound Repair and Regeneration | 2018

von Gallant‐Behm, C. | Piper, J. | Dickinson, B. | +3

8

Treatment of renal cell carcinoma with anti-CD70 antibody-drug conjugates

enthalten in: Europäisches Patentamt | 2016

von LAW CHE-LEUNG | WAHL ALAN F | SCHOLLER NATHALIE | +1

9

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

enthalten in: Investigational new drugs | 2012

von Ramanathan, R. | Stephenson, J. | Weiss, G. | +7

10

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

enthalten in: Investigational new drugs | 2011

von Ramanathan, R. | Stephenson, J. | Weiss, G. | +7